

# Câncer de Pulmão de Pequenas Células

## **EP + Radioterapia**

Etoposide: 100mg/m<sup>2</sup> IV D1 ao D3

Cisplatina: 80mg/m<sup>2</sup> IV D1

a cada 28 dias no total de 4 ciclos, concomitante a radioterapia

Ref. (1)

## **CAV seguido de EP + Radioterapia**

Ciclofosfamida: 1000 mg/m<sup>2</sup> IV D1

Doxorrubicina: 50 mg/m<sup>2</sup> IV D1

Vincristina: 1mg/m<sup>2</sup> IV D1 (máximo 2mg)

3 semanas após CAV, administrar EP.

Alternar CAV e EP a cada 3 semanas.

Etoposide: 100mg/m<sup>2</sup> IV D22 ao D24

Cisplatina: 25mg/m<sup>2</sup> IV D22

Iniciar radioterapia torácica 20 a 30 Gy concomitante ao EP

Ref. (2)

## **EP**

Etoposide: 120 mg/m<sup>2</sup> IV D1 ao D3 ou etoposide 120mg/m<sup>2</sup> IV D1 e 240mg/m<sup>2</sup> VO D2 e D3

Cisplatina: 80 mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (3)

## **EC**

Etoposide: 100 mg/m<sup>2</sup> IV D1 ao D3

Carboplatina: AUC de 6 IV D1

a cada 28 dias

Ref. (4)

### **Irinotecano + Cisplatina**

Irinotecano: 60 mg/m<sup>2</sup> IV D1, D8 e D15

Cisplatina: 60 mg/m<sup>2</sup> IV D1

a cada 28 dias

Ref. (5)

### **Carboplatina + Irinotecano**

Carboplatina: AUC de 4 IV D1

Irinotecano: 175mg/m<sup>2</sup> IV D1

a cada 21 dias

Ref. (6)

### **Carboplatina + Paclitaxel**

Paclitaxel: 200mg/m<sup>2</sup> IV D1

Carboplatina: AUC 6 IV D1

a cada 21 dias

Ref. (7)

### **Carboplatina + Paclitaxel + Etoposide**

Carboplatina: AUC 6 IV D1

Paclitaxel: 200 mg/m<sup>2</sup> IV durante 1 hora D1

Etoposide: 50 mg alternando com 100 mg VO D1 ao D10

a cada 21 dias

Ref. (8)

### **CAE**

Ciclofosfamida: 1000mg/m<sup>2</sup> IV D1

Doxorrubicina: 50mg/m<sup>2</sup> IV D1

Etoposide: 120mg/m<sup>2</sup> IV D1 e 240mg/m<sup>2</sup> VO D2 e D3

a cada 21 dias

Ref. (9)

### **Paclitaxel**

Paclitaxel: 80-100 mg/m<sup>2</sup> IV semanalmente por 3 semanas

a cada 28 dias

Ref. (10)

## Topotecano

Topotecano: 4mg/m<sup>2</sup> IV semanalmente em 30 minutos

### OU

Topotecano: 2,3mg/m<sup>2</sup> VO D1 ao D5

a cada 21 dias

Ref. (11)

1. Takada M. *et al.* Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104. *J Clin Oncol* 20:3054, 2002.
2. Murray N. *et al.* Abbreviated treatment for elderly, infirm or noncompliant patients with limited-stage small-cell lung cancer. *J Clin Oncol* 16: 3323, 1998.
3. Ihde DC, *et al.* Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive stage small cell lung cancer. *J Clin Oncol* 1994;12:2022-2034.  
Baka S. *et al.* Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. *Br J Cancer* 99: 442, 2008
4. Viren M, *et al.* Carboplatin and etoposide in extensive small cell lung cancer. *Acta Oncol* 1994;33:921-924.
5. Noda K, *et al.* Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. *N Engl J Med* 2002;346:85-91.
6. Hermes A. *et al.* Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial. *J Clin Oncol* 26: 4261, 2008.
7. Baka S. *et al.* Randomized phase III study of carboplatin and paclitaxel versus vincristine, doxorubicin and cyclophosphamide

chemotherapy in intermediate and poor prognosis small cell lung cancer: Preliminary results. *J Clin Oncol* 24: abstr 7059, 2006.

8. Hainsworth JD, *et al.* Paclitaxel, carboplatin and extended-schedule etoposide in the treatment of small cell lung cancer comparison of sequential phase II trials using different dose-intensities. *J Clin Oncol* 1997;15:3464-3470.
9. Baka S. *et al.* Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. *Br J Cancer* 99: 442, 2008.
10. Hainsworth JD, *et al.* The current role and future prospects of paclitaxelin in the treatment of small cell lung cancer. *Semin Oncol* 1999;26 (Suppl 2):60-66.
11. Shipley D. L. *et al.* Topotecan: Weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)—A Minnie Pearl Cancer Research Network phase II trial . *J Clin Oncol* 24: abstr 7083, 2006.

Mary E.R.*et al.* Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer. *J Clin Oncol* 24: 5441, 2006.